GAO: UDI, funding shortfalls weaken FDA’s active surveillance program for devices
Regulatory NewsJoanne S. Eglovitch
CDRHMarket withdrawalMedical device reportingMedical DevicesPatient registriesPharmacovigilanceProduct LifecycleRecallsUnited StatesUS Food and Drug Administration (FDA)